ALT-803联合纳武利尤单抗治疗转移性非小细胞肺癌的1b期试验
这项非随机、开放标签1b期试验在既往治疗的IIIB或IV期NSCLC患者中评估IL-15超激动剂ALT-803联合纳武利尤单抗的安全性、耐受性和活性。21例可评估患者中未记录剂量限制性毒性,未达到最大耐受剂量,最常见不良事件为注射部位反应和流感样症状。推荐2期剂量为ALT-803 20 μg/kg每周皮下注射联合纳武利尤单抗240 mg每2周静脉注射。
要点
- ALT-803联合纳武利尤单抗未达最大耐受剂量,无剂量限制性毒性。
- 最常见不良事件为注射部位反应(90%)和流感样症状(71%)。
- 推荐2期剂量为ALT-803 20 μg/kg每周皮下联合纳武利尤单抗240 mg每2周。
核心结论
- ALT-803联合纳武利尤单抗可在门诊安全给药,并在PD-1抗体难治性NSCLC中显示抗肿瘤活性证据。
研究设计与样本
- 非随机、开放标签1b期试验,自美国3家学术医院入组既往治疗的IIIB或IV期NSCLC患者。
- 2016年1月18日至2017年6月28日入组23例,21例接受ALT-803四个递增剂量(6、10、15或20 μg/kg)联合纳武利尤单抗治疗。
- 主要终点为安全性和耐受性及确定ALT-803联合纳武利尤单抗的推荐2期剂量。
主要发现
- 未记录剂量限制性毒性,未达到最大耐受剂量。
- 最常见不良事件为注射部位反应(21例中19例,90%)和流感样症状(21例中15例,71%)。
- 最常见的3级不良事件为淋巴细胞减少和疲乏,各发生于2例患者;1例患者发生3级心肌梗死。
- 未记录4级或5级不良事件。
关键数值与推荐
- 推荐2期剂量为ALT-803 20 μg/kg每周皮下注射联合纳武利尤单抗240 mg每2周静脉注射。
临床怎么用
- ALT-803联合纳武利尤单抗可在门诊环境中安全给药,支持进一步在NSCLC中评估该联合方案。
局限性
- 为非随机、开放标签1b期试验,样本量小(21例接受治疗),未设对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunotherapy with PD-1 or PD-L1 blockade fails to induce a response in about 80% of patients with unselected non-small cell lung cancer (NSCLC), and many of those who do initially respond then develop resistance to treatment. Agonists that target the shared interleukin-2 (IL-2) and IL-15Rβγ pathway have induced complete and durable responses in some cancers, but no studies have been done to assess the safety or efficacy of these agonists in combination with anti-PD-1 immunotherapy. We aimed to define the safety, tolerability, and activity of this drug combination in patients with NSCLC. METHODS: In this non-randomised, open-label, phase 1b trial, we enrolled patients (aged ≥18 years) with previously treated histologically or cytologically confirmed stage IIIB or IV NSCLC from three academic hospitals in the USA. Key eligibility criteria included measurable disease, eligibility to receive anti-PD-1 immunotherapy, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received the anti-PD-1 monoclonal antibody nivolumab intravenously at 3 mg/kg (then 240 mg when US Food and Drug Administration [FDA]-approved dosing changed) every 14 days (either as new treatment or continued treatment at the time of disease progression) and the IL-15 superagonist ALT-803 subcutaneously once per week on weeks 1-5 of four 6-week cycles for 6 months. ALT-803 was administered at one of four escalating dose concentrations: 6, 10, 15, or 20 μg/kg. The primary endpoint was to define safety and tolerability and to establish a recommended phase 2 dose of ALT-803 in combination with nivolumab. Analyses were per-protocol and included any patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT02523469; phase 2 enrolment of patients is ongoing. FINDINGS: Between Jan 18, 2016, and June 28, 2017, 23 patients were enrolled and 21 were treated at four dose levels of ALT-803 in combination with nivolumab. Two patients did not receive treatment because of the development of inter-current illness during enrolment, one patient due to leucopenia and one patient due to pulmonary dysfunction. No dose-limiting toxicities were recorded and the maximum tolerated dose was not reached. The most common adverse events were injection-site reactions (in 19 [90%] of 21 patients) and flu-like symptoms (15 [71%]). The most common grade 3 adverse events, occurring in two patients each, were lymphocytopenia and fatigue. A grade 3 myocardial infarction occurred in one patient. No grade 4 or 5 adverse events were recorded. The recommended phase 2 dose of ALT-803 is 20 μg/kg given once per week subcutaneously in combination with 240 mg intravenous nivolumab every 2 weeks. INTERPRETATION: ALT-803 in combination with nivolumab can be safely administered in an outpatient setting. The promising clinical activity observed with the addition of ALT-803 to the regimen of patients with PD-1 monoclonal antibody relapsed and refractory disease shows evidence of anti-tumour activity for a new class of agents in NSCLC. FUNDING: Altor BioScience (a NantWorks company), National Institutes of Health, and Medical University of South Carolina Hollings Cancer Center.
引用
- Wrangle JM, Velcheti V, Patel MR, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018. PMID: 29628312. doi:10.1016/S1470-2045(18)30148-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。